Trials / Conditions / MDS (Myelodysplastic Syndrome)

MDS (Myelodysplastic Syndrome)

22 registered clinical trials studyying MDS (Myelodysplastic Syndrome) — 16 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patient NCT07500753	The First Affiliated Hospital of Soochow University	N/A
Not Yet Recruiting	A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies NCT06906380	ARCE Therapeutics, Inc.	—
Recruiting	WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Expl NCT07511829	University of Oxford	—
Recruiting	Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA NCT07400341	The First Affiliated Hospital of Soochow University	Phase 2
Not Yet Recruiting	Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantat NCT07214064	University Hospital Tuebingen	Phase 2
Recruiting	Luspatercept + Darbepoetin in MDS NCT07096297	Yale University	Phase 2
Recruiting	Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantati NCT07297576	Institute of Hematology & Blood Diseases Hospital, China	N/A
Not Yet Recruiting	Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoin NCT07025824	Technische Universität Dresden	Phase 2
Recruiting	A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxi NCT06859424	Center for International Blood and Marrow Transplant Research	Phase 2
Recruiting	Romiplostim N01 for Platelet Recovery After Haploidentical HSCT NCT07321626	First Affiliated Hospital of Zhejiang University	Phase 1
Recruiting	Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS NCT06680752	ARCE Therapeutics, Inc.	Phase 1 / Phase 2
Recruiting	A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malign NCT07347171	Cullgen (Shanghai),Inc	Phase 1
Recruiting	Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HS NCT06839456	Children's Hospital of Philadelphia	Phase 1 / Phase 2
Recruiting	A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Tr NCT05589896	Ossium Health, Inc.	Phase 1 / Phase 2
Recruiting	Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation NCT06892223	Istituto Clinico Humanitas	Phase 2
Completed	Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clini NCT04212390	Fondazione Italiana Sindromi Mielodisplastiche-ETS	—
Terminated	Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders NCT03198234	Roncarolo, Maria Grazia, MD	Phase 1
Terminated	Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Tra NCT02231853	National Heart, Lung, and Blood Institute (NHLBI)	Phase 1
Terminated	Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS) NCT02093429	Incyte Corporation	Phase 1 / Phase 2
Completed	Preventing Stem Cell Transplant Complications With a Blood Separator Machine NCT01866839	National Heart, Lung, and Blood Institute (NHLBI)	Phase 1 / Phase 2
Recruiting	Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Sy NCT01174108	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2
Completed	Stem Cell Transplantation for Patients With Cancers of the Blood NCT00467961	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2